WAR 1.6 2011 BY

Exhibit A

David J. Pinsky et al. U.S. Serial No.:09/053,871 Filed: April 1, 1998 Page 1

Exhibit A - Marked up version of claims showing all changes relative to the previous version of that claim:

--29. (amended) A method of inhibiting clot formation in a subject which comprises adding to blood an amount of an inactive recombinant mutein in an amount effective to inhibit clot formation in the subject but which does not significantly interfere with hemostasis when the blood is administered to a patient,

wherein the inactive recombinant mutein comprises:

- (a) a proteolytically inactive recombinant mutein of Factor IX, or
- (b) a proteolytically inactive recombinant mutein of Factor IXa

and wherein the recombinant mutein comprises a substitution, [deletion,] or addition of one or more amino acids to an active site of wild-type Factor IX or an active site of wild-type Factor IXa resulting in reduced ability to convert Factor X to Factor Xa.--

--36.(amended) The method of claim 29, wherein the recombinant mutein of Factor IX comprises [consists essentially of] [amino acids 1-47 of Factor IX, and further